Source link : https://www.newshealth.biz/health-news/published-data-show-why-gsk-bailed-on-its-maternal-rsv-vaccine/
GSK’s abandoned maternal respiratory syncytial virus (RSV) vaccine protected infants from severe RSV, final results of a phase III trial indicated, but those positive outcomes came at the expense of an unexplained higher risk for preterm birth. For newborns up to 6 months of age, efficacy with the RSV prefusion F protein-based vaccine (RSVPreF3-Mat) during […]
Author : News Health
Publish date : 2024-03-13 17:32:31
Copyright for syndicated content belongs to the linked Source.
in Health